Inaktiver Wert

Andere Sprachen LOTUS PHARM OTC Bulletin Board

Aktien

LTUS

US5457151042

LTUS

Schlusskurs OTC Bulletin Board Andere Börsenplätze
- ^USD	-

2023

Amarin und Lotus Pharmaceuticals vereinbaren exklusiven Vertrieb von Vazkepa in 10 asiatischen Ländern

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lotus Pharmaceuticals Secures Three HR Asia Awards for 2024	08.07.
Lotus Pharmaceuticals announces the acquisition of Teva Pharma Thailand, expanding its footprint in Southeast Asia	07.06.
Lotus Achieves Historic Q3 2023 Results with YTD EPS Soaring to a Record NTD 14.19 Marking a 29% Year-on-Year Growth	10.11.
Lotus Continued Stelar Growth in 2Q 2023 EPS Recorded NTD 4.85 with 285% Growth Year on Year	12.09.23
Lotus Continued Stelar Growth in 2Q 2023 EPS Recorded NTD 4.85 with 285% Growth Year on Year	14.08.23
AMARIN AND LOTUS PHARMACEUTICALS ANNOUNCE EXCLUSIVE PARTNERSHIP AGREEMENT TO COMMERCIALIZE VAZKEPA IN SOUTHEAST ASIA AND SOUTH KOREA	01.08.23
Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	31.07.23
Lotus Announces MFDS Approval for GRALISE SR, Once-Daily Tablets for Post-Herpetic Neuralgia	27.03.23
Lotus revenues grow by 16% and profit doubles year over year	13.03.23
Lotus acquires Alimta in Taiwan from Lilly	14.12.22
Lotus Pharmaceuticals - Aztiq and Innobic officially become Lotus's majority shareholders	12.07.22
Lotus Reports Solid Performance in First Quarter of 2022	16.05.22
Lotus Pharmaceuticals : Unaudited Financial Statement	30.03.22
Lotus Pharmaceuticals acquires Cialis (Tadalafil) in Taiwan from Lilly	23.03.22
Lotus achieves another record high EPS for FY2021	17.03.22
A powerful investment alliance of Aztiq and Innobic acquires Alvogen's shares in Lotus and Adalvo in a US$475m deal	29.11.21
Thai oil firm PTT expands pharma business with $475 million Alvogen deal	26.11.21
Lotus Pharmaceuticals : Informational Disclosure	22.11.21
Lotus Pharmaceuticals : Unaudited Financial Statements	22.11.21
Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	28.09.21

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen LOTUS PHARM OTC Bulletin Board

Aktien

LTUS

US5457151042

LTUS

Andere Sprachen

Filter